Nordic Nanovector

334 articles with Nordic Nanovector

• Nordic Nanovector To Be Included In Oslo Børs OBX Index

  6/9/2017

• Nordic Nanovector Release: Accepted Abstract By ICML With Updated Results From Phase I/II Trial Of Betalutin In NHL Is Now Available On-Line

  6/8/2017

• Nordic Nanovector: Allocation Of Restricted Stock Units (RSUs) To The Board Of Directors

  6/2/2017

• Nordic Nanovector - Results For First Quarter 2017

  5/24/2017

• Nordic Nanovector Release: Safety Review Committee Approves The Continued Evaluation Of The 20 Mbq/Kg Betalutin With 100 Mg/M2 Lilotomab Regimen In Phase ll Cohort In NHL

  5/19/2017

• Nordic Nanovector: Invitation To First Quarter 2017 Results Presentation And Webcast

  5/16/2017

• Nordic Nanovector: Notice Of Annual General Meeting On 24 May 2017

  5/2/2017

• Nordic Nanovector Release: Updated Results From Phase I/II Trial Of Betalutin In NHL Accepted For Presentation At The International Conference On Malignant Lymphoma In June

  4/28/2017

• Nordic Nanovector - Financial Calendar

  3/27/2017

• Nordic Nanovector Publishes Annual Report 2016

  3/24/2017

• Nordic Nanovector Announces First Patient Dosed In Phase I Study Of Betalutin In Diffuse Large B-Cell Lymphoma (DLBCL), An Aggressive Form Of NHL

  3/17/2017

• Nordic Nanovector - Results For Fourth Quarter And Full Year 2016

  2/28/2017

• Nordic Nanovector: Invitation To Fourth Quarter And Full Year 2016 Results Presentation And Webcast

  2/22/2017

• Nordic Nanovector: Share Options Granted, Including Options To Primary Insiders

  2/2/2017

• Nordic Nanovector: Share Capital Increase Registered

  2/2/2017

• Nordic Nanovector: Mandatory Notification Of Trade - Primary Insiders

  12/9/2016

• Nordic Nanovector: Betalutin In Combination With Rituximab Demonstrates Synergistic Anti-Tumour Effect In Preclinical Non-Hodgkin Lymphoma Model

  12/6/2016

• Nordic Nanovector: Single-Dose Betalutin Shows Promising Efficacy, Improved Duration Of Response And Favourable Safety In Relapsed NHL Patients

  12/5/2016

• Nordic Nanovector– Results For Third Quarter 2016

  11/23/2016

• Nordic Nanovector Appoints Lisa Rojkjaer, MD As Chief Medical Officer

  11/15/2016